MAPT and Alzheimer disease: Soluble varieties of phosphorylated tau (pTau) at specific epitopes such as threonine 231 (pTau231) and threonine 181 (pTau181) are established markers of AD pathology in brain and serve as early biomarkers in the CSF [8].